Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$13,385 Mln
P/E Ratio
--
P/B Ratio
1.23
Industry P/E
--
Debt to Equity
0.07
ROE
-0.29 %
ROCE
-26.67 %
Div. Yield
0 %
Book Value
28.39
EPS
-9.27
CFO
$16,449.87 Mln
EBITDA
$17,992.53 Mln
Net Profit
$13,724.47 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Moderna (MRNA)
| -16.52 | 5.21 | -17.04 | -66.58 | -41.04 | 5.55 | -- |
|
BSE Sensex*
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Moderna (MRNA)
| -57.89 | -44.63 | -29.28 | 143.11 | 434.10 | 28.09 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.02 | 10,257.64 | 20.82 | 23.13 | |
| 326.34 | 9,900.19 | 25.71 | 58.42 | |
| 111.50 | 11,042.16 | 33.66 | 14.16 | |
| 101.35 | 9,430.55 | 41.53 | 19.71 |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic... influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 325 Binney Street, Cambridge, MA, United States, 02142 Read more
CEO & Director
Mr. Stephane Bancel
CEO & Director
Mr. Stephane Bancel
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Moderna Inc (MRNA) stood at $ 14,142 Mln as on 31-Dec-24
The share price of Moderna Inc (MRNA) is $34.71 (NASDAQ) as of 17-Mar-2025 16:23 EDT. Moderna Inc (MRNA) has given a return of -41.04% in the last 3 years.
Moderna Inc (MRNA) has a market capitalisation of $ 13,385 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Moderna Inc (MRNA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Moderna Inc (MRNA) and enter the required number of quantities and click on buy to purchase the shares of Moderna Inc (MRNA).
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 325 Binney Street, Cambridge, MA, United States, 02142
The CEO & director of Mr. Stephane Bancel. is Moderna Inc (MRNA), and CFO & Sr. VP is Mr. Stephane Bancel.
There is no promoter pledging in Moderna Inc (MRNA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
|
|
988
|
| Moderna Inc. (MRNA) | Ratios |
|---|---|
|
Return on equity(%)
|
-28.77
|
|
Operating margin(%)
|
-110.72
|
|
Net Margin(%)
|
-110.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Moderna Inc (MRNA) was $-3,561 Mln.
$0.09
(
